|
Market Closed -
Nasdaq
16:00:00 2026-08-25 EDT
|
5-day change | 1st Jan Change | ||
| 220.77 USD | +1.21% |
|
+3.87% | +25.44% |
| 08-25 | Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients | MT |
| 08-25 | RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating | MT |
Company Valuation: Biogen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,242 | 39,877 | 37,495 | 22,283 | 25,818 | 32,620 | - | - |
| Change | - | 13.15% | -5.97% | -40.57% | 15.86% | 26.34% | - | - |
| Enterprise Value (EV) 1 | 37,820 | 40,560 | 43,384 | 26,204 | 28,289 | 37,556 | 35,040 | 31,967 |
| Change | - | 7.24% | 6.96% | -39.6% | 7.96% | 32.76% | -6.7% | -8.77% |
| P/E | 23.1x | 13.3x | 32.5x | 13.7x | 20x | 39.2x | 19.3x | 15.5x |
| PBR | 3.26x | 3.02x | 2.53x | 1.33x | 1.42x | 1.76x | 1.6x | 1.45x |
| PEG | - | 0x | -0.5x | 0.3x | -0.9x | -1.1x | 0x | 0.6x |
| Capitalization / Revenue | 3.21x | 3.92x | 3.81x | 2.3x | 2.61x | 3.12x | 3.06x | 2.98x |
| EV / Revenue | 3.44x | 3.99x | 4.41x | 2.71x | 2.86x | 3.6x | 3.29x | 2.92x |
| EV / EBITDA | 9.13x | 11.2x | 14.3x | 7.1x | 7.82x | 13.7x | 10.1x | 8.74x |
| EV / EBIT | 10.3x | 13.1x | 17x | 8.69x | 9.97x | 14.9x | 10.9x | 9.11x |
| EV / FCF | 11.2x | 35.5x | 34.2x | 9.63x | 13.8x | 20.2x | 14.8x | 11.8x |
| FCF Yield | 8.94% | 2.82% | 2.93% | 10.4% | 7.25% | 4.95% | 6.77% | 8.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 10.4 | 20.87 | 7.97 | 11.18 | 8.79 | 5.628 | 11.41 | 14.22 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 | 10,442 | 10,659 | 10,959 |
| EBITDA 1 | 4,144 | 3,618 | 3,040 | 3,689 | 3,618 | 2,740 | 3,453 | 3,656 |
| EBIT 1 | 3,656 | 3,099 | 2,545 | 3,015 | 2,838 | 2,514 | 3,203 | 3,511 |
| Net income 1 | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 | 953.1 | 1,899 | 2,247 |
| Net Debt 1 | 2,578 | 683 | 5,888 | 3,921 | 2,471 | 4,937 | 2,420 | -652.2 |
| Reference price 2 | 239.92 | 276.92 | 258.77 | 152.92 | 175.99 | 220.77 | 220.77 | 220.77 |
| Nbr of stocks (in thousands) | 146,893 | 144,001 | 144,898 | 145,719 | 146,702 | 147,754 | - | - |
| Announcement Date | 2/3/22 | 2/15/23 | 2/13/24 | 2/12/25 | 2/6/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 39.23x | 3.6x | 13.71x | -.--% | 32.62B | |
| 19.3x | 4.51x | 10.63x | 0.47% | 83.24B | |
| 20.45x | 4.36x | 13.46x | 2.43% | 59.49B | |
| -18.57x | 28.37x | -18.46x | -.--% | 63.41B | |
| 38.56x | 13.17x | 25.26x | -.--% | 52.94B | |
| 22.44x | 4.95x | 14.13x | 0.65% | 49.86B | |
| 57.89x | 3.71x | 28.77x | -.--% | 26.29B | |
| 72.74x | 7.16x | 48.17x | -.--% | 22.23B | |
| 24.61x | 5.28x | 13.74x | -.--% | 17.22B | |
| 71.74x | 43.18x | 62.7x | 0.15% | 15.36B | |
| Average | 34.84x | 11.83x | 21.21x | 0.37% | 42.27B | |
| Weighted average by Cap. | 25.44x | 10.66x | 14.27x | 0.52% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BIIB Stock
- Valuation Biogen Inc.
Select your edition
All financial news and data tailored to specific country editions
